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Abstract  
Objective: To investigate the prevalence and determinants of virologic failure (VF) and 
acquired drug resistance-associated mutations (DRM) in HIV-infected children and 
adolescents in rural Tanzania. 
 
Design: Prospective cohort study with cross-sectional analysis. 
 
Methods: All children ≤18 years attending the paediatric HIV Clinic of Ifakara and on 
antiretroviral treatment (ART) for ≥12 months were enrolled. Participants with VF were 
tested for HIV-DRM. Pre-ART samples were used to discriminate acquired and transmitted 
resistances. Multivariate logistic regression analysis identified factors associated with VF and 
the acquisition of HIV-DRM. 
 
Results: Among 213 children on ART for a median of 4.3 years, 25.4% failed virologically. 
ART-associated DRM were identified in 90%, with multiclass resistances in 79%. Pre-ART 
data suggested that >85% had acquired key mutations during treatment. Suboptimal 
adherence [OR=3.90; 95%CI 1.11-13.68], female sex [OR=2.57; 95%CI 1.03-6.45], and 
current non-nucleoside reverse transcriptase inhibitor-based ART [OR=7.32; 95%CI 1.51-
35.46 compared to protease inhibitor-based] independently increased the odds of VF. CD4
+ 
T 
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cell percentage [OR=0.20; 0.10-0.40 per additional 10%] and older age at ART initiation 
[OR=0.84per additional year-of-age; 95%CI 0.73 to 0.97] were protective (also in predicting 
acquired HIV-DRM). At the time of VF, less than 5% of the children fulfilled the WHO 
criteria for immunologic failure. 
 
Conclusion: VF rates in children and adolescents were high, with the majority of ART-failing 
children harbouring HIV-DRM. The WHO criteria for immunologic treatment failure yielded 
an unacceptably low sensitivity. Viral load monitoring is urgently needed to maintain future 
treatment options for the millions of African children living with HIV. 
 
Keywords: HIV, antiretroviral therapy, resistance, viral failure, children, Africa, resource-
limited settings; adolescents 
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Background 
In 2015, 1.8 million children were living with HIV worldwide, the vast majority in sub-
Saharan Africa (SSA) [1-2]. The roll-out of antiretroviral therapy (ART) in resource-limited 
countries has resulted in a reduction of HIV-related morbidities and mortality and an 
increased life expectancy of infected adults and children [3-4]. However, globally only 49% 
of the children in need have access to treatment [5]. In addition to the low ART coverage in 
children, long-term treatment success and virologic suppression are harder to achieve in this 
population [7], mostly due to high pre-ART viral loads and the risk of sub-therapeutic drug 
concentrations caused by limited paediatric drug formulations, variable pharmacokinetics, and 
continuous bodyweight changes [8-10].  
The lack of reliable HIV rapid tests for infants and the limited treatment monitoring in most 
resource-limited settings, often combined with advanced immunosuppression at ART 
initiation, further aggravate treatment outcomes [6,11]. Together with the challenge of 
adherence during childhood and adolescence, these factors promote the emergence of HIV 
drug-resistance mutations (HIV-DRM) [10,12]. Moreover, although multiple studies confirm 
that immunological and clinical criteria fail to timely detect treatment failure among children 
and adolescents [13-15], most resource-limited settings do not have plasma HIV RNA viral 
load (VL) monitoring available [16]. Given the limited ART options in SSA, the emergence 
of newly acquired HIV-DRM in children is likely to lead to poor clinical outcomes including 
a reduced survival. 
Two recent systematic reviews on the effectiveness of ART among children found virologic 
success rates of 40% to 81% after twelve months on treatment [6,17]. Recently, not yet 
published data collected by the Tanzanian CDC comparing fifteen different settings across the 
country demonstrated a high average virologic failure (VF) rate of 38.8% among children, 
with HIV-DRM found in 84.4% of the failing children. 
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We assessed the prevalence and determinants of VF and acquired HIV-DRM after long-term 
ART exposure within a large paediatric HIV cohort in rural Tanzania.  
Patients and methods 
Study site and population 
All data were prospectively collected from participants enrolled in the Kilombero and Ulanga 
Antiretroviral Cohort (KIULARCO) after getting informed consent from the patient or 
caregiver if younger than 19 years. This ongoing, open, prospective cohort is comprised of all 
patients enrolled at the Chronic Diseases Clinic of Ifakara, which serves as a Care and 
Treatment Centre for HIV/AIDS patients within the Saint Francis Referral Hospital. This is 
the largest health care facility in the Kilombero district, in southern Tanzania, providing 
treatment and care for a population of approximately 600,000 inhabitants and estimated 
38,000 people living with HIV. Established in 2004, this was the first rural clinic accredited to 
be a Care and Treatment Centre of the National AIDS Control Program in the country, and 
over 9000 patients have been enrolled into care. Since 2013 the Chronic Diseases Clinic has a 
family-centred unit named the “One Stop Clinic of Ifakara”, where care to HIV-infected 
children, mothers and their families is provided by a specially trained team [18-19]. 
At each clinical visit, comprehensive clinical data is systematically collected through 
electronic medical records. Blood samples are drawn at routine clinic visits before ART 
initiation, two weeks, 3 months and every 6 months thereafter. Plasma is cryopreserved at -
80ºC [20-22].  
All HIV-infected children and adolescents aged ≤18 years enrolled in KIULARCO and who 
had been on ART for at least twelve months were included in this study.   
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Viral load testing and HIV genotyping 
Blood samples were collected in 8mL BD Vacutainer EDTA collection tubes. Cell-free 
plasma was collected by centrifugation at 956 g for 5 minutes and frozen at -800C until 
testing for HIV RNA VL or viral drug-resistance. Assays for VL and sequencing for HIV 
drug-resistance were performed at the Ifakara Health Institute laboratory in Ifakara. HIV RNA 
from 400µL plasma was extracted using the NucleoSpin® Virus kit (Macherey-Nagel, 
Oensingen, Switzerland) according to the manufacturer‟s protocol. Viral RNA quantification 
was performed using a validated in-house protocol [23] with the Brilliant III Ultra-Fast QRT-
PCR Master Mix (Agilent Technologies, La Jolla CA, USA) using the StepOneTM Real-
Time PCR System (Applied Biosystems, Foster City CA, USA), with a detection limit of 200 
viral RNA copies/mL of plasma. HIV drug-resistance genotyping was performed by Sanger 
sequencing on a 3130 Genetic Analyser 4-capillary model (Applied Biosystems, Foster City 
CA, USA) using a validated in-house PCR protocol [23]. 
 
Statistical analysis 
The primary outcomes were VF, defined as a viral RNA level of ≥1000 copies/mL after at 
least twelve months on ART, and the acquisition of major HIV-1 DRM in failing patients. For 
data description, the numeric variables were displayed with medians and interquartile ranges 
(IQRs) whereas the categorical variables were presented in proportions. Associations between 
considered variables and VF and HIV-DRM were assessed using multivariate logistic 
regression models. All analyses were performed using STATA, version 14 (Stata Corporation, 
College Station, TX, USA). 
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Ethical approval 
The KIULARCO study received ethical approval from the Ifakara Health Institute 
Institutional Review Board, the National Institute for Medical Research of Tanzania, the 
Tanzanian Commission of Science and Technology, and the Ethics Committee of the 
University and State of Basel.  
 
 
Results 
Characteristics of study population 
At the time of analysis, 241 children and adolescents had been on ART for longer than 12 
months. Twenty-eight patients were excluded due to several causes (Figure 1). The remaining 
213 children contributed 902.2 person-years of follow-up. The characteristics of the study 
participants are described in Table 1. The median age was eleven years (IQR 7.5 – 14.4) and 
43% were female. Fifty-five per cent were classified as WHO clinical stage 3 or 4, the median 
CD4 percentage was 12.2% (IQR 6.3-19.3) and 12.4% reported prior antiretroviral exposure 
at the time of enrolment in the cohort, excluding exposure to the mother‟s antiretroviral in-
utero or through breast milk.  
Initial regimen consisted mostly of co-formulated zidovudine (AZT)/ lamivudine (3TC) with 
a non-nucleoside reverse transcriptase inhibitor (NNRTI) in 54.9% children, whereas 
stavudine (d4T) / 3TC with nevirapine (NVP) was used in 39% of the participants. At the time 
of investigation, the median time on ART was 4.45 years (IQR 2.4 – 6.0), 84% were on an 
NNRTI-based regimen and 15% (32/213) on a boosted protease inhibitor (PI)-based regimen, 
28 of them as a second-line treatment. The decision to switch to a second-line regimen had 
been based on clinical and immunological criteria, as VL monitoring had not been available 
for routine monitoring of treatment success. Eighty-six percent reported good adherence to 
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ART (defined as no missed doses during the last four weeks) and 23.5% had experienced 
ART regimen changes due to drugs unavailability or shortage, with a median of three regimen 
switches (range 0-16). Ten children (4.7%) were reported to be lost to follow-up since the last 
clinical visit. 
 
Virologic outcome 
At the time of investigation, 159/213 (74.6%) participants had viral plasma levels below the 
WHO threshold for VF (<1000 copies/mL). In total, 92/213 children and adolescents (43.2%, 
95% CI 36.5 – 49.8) had detectable HIV-1 in plasma. Fifty-four children (25.4%, 95% CI 
19.5 - 31.2) had VF with a median VL of 20615 copies/mL, and 38 (17.8%, 95% CI 12.7 – 
23.0) had detectable viral plasma levels below the WHO threshold: 26 (12.2%) <500 
copies/mL, and 12 (5.6%) between 500 and 1000 copies/mL. Forty-six of the 54 patients with 
VF were on a first-line ART regimen and eight on second-line treatment. Patients presenting 
VF were switched to a new ART regimen according to the genotype produced during this 
study. 
 
Immunologic response after ART initiation and virologic outcome 
The average number of CD4+ T cell percentage (CD4%) measurements from the 213 
participants was six (range 1-16). The median CD4% rose from 12.2% at ART initiation to 
26% after twelve months on treatment, reaching a maximum of 30.5% after 60 to 66 months 
on ART. By comparing the CD4% recovery of patients with and without VF (Figure 2), the 
immune cell recovery in those with VF tended to be diminished, reaching only 22% after 12 
months, compared to 27.5% among patients without VF. This difference, however, did not 
reach statistical significance. Although there was a trend for lower CD4% among participants 
with VF, they also showed a median CD4% recovery after ART initiation, which remained 
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
stable at or above 20%. In this group, the median CD4% after treatment initiation never 
dropped below the threshold of 10%, a criteria of immunological failure in children below 
five years [24], and the median CD4+ T cell count stabilised above 500 cells/µL.  
 
Predictors of virologic failure 
NNRTI-based ART at the time of analysis (OR=7.32 [95% CI 1.51-35.46], p= 0.013), 
suboptimal adherence (OR=3.90 [95% CI 1.11-13.68], p= 0.034), and female sex (OR=2.57 
[95% CI 1.03-6.45], p= 0.044) were independently associated with VF. Higher CD4 counts 
(OR=0.20 per additional 10% [95% CI 0.10 - 0.41], p< 0.001) and older age at ART initiation 
(OR=0.84 per additional year of age at treatment initiation, [95% CI 0.73-0.97], p = 0.017) 
were protective of VF (Table 2). 
 
HIV drug resistance mutations 
The viral genome was successfully sequenced from 52/54 children and adolescents with VF. 
Forty-seven (90.4% [95% CI 82.4 - 98.4]) harboured at least one major HIV-DRM at the time 
of VF. Among patients with HIV-DRM, resistance to nucleoside/nucleotide reverse 
transcriptase inhibitors (NRTI) and NNRTI was found in 80.8% (95% CI 70.1 - 91.5) and 
90.2%(95% CI 82.0- 98.4), respectively. Seventy-nine per cent (95% CI 67.7 - 89.9) had 
major drug resistance against both drug classes. No major PI-associated drug resistance 
mutations were found. Thirteen patients presented with minor PI-associated drug resistance 
mutations, which did not limit the activity of any PI.  
The most common resistance mutations were M184V/MV, triggering high-level resistance to 
3TC and emtricitabine, found in 40/52 (77%) patients; K103N/KN, causing high-level 
resistance to efavirenz and NVP, in 25/52 (49%); and Y181C/YC/V, leading to high-level 
resistance against NVP, in 16/52 (31%). Eighteen patients (34.6%) had detectable thymidine 
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analogue resistance mutations (TAMs), including M41L, D67N, K70R, T215F/Y and 
K219Q/E, with T215F/Y being the most common and found in 13 (25%) children. Notably, 
the K65R mutation was present in three adolescents, who had no history of tenofovir 
disoproxil fumarate (TDF) exposure (Table 3). The minor PI mutations detected were L10 
polymorphisms in eight patients, T74S in four and L76I in two. Four of the thirteen patients 
with minor PI mutations were on a PI-based regimen (all with LPV/r), whereas the other nine 
had never been exposed to PIs. From the 52 available viral genomes from HIV-1 infected 
children and adolescents, 44.2% (23/52) were subtype C, 32.7% (17/52) subtype A, 21.2% 
(11/52) subtype D, and the pol gene of one child (1.9%) consisted of a subtype A protease and 
subtype D reverse transcriptase. This subtype distribution was consistent with the reported 
viral subtype circulation in treatment-naïve patients in Ifakara from 2009 [23]. 
 
Acquisition of drug resistance mutations after treatment initiation 
Additional data was available from 44/47 participants with detected HIV-DRM to verify the 
acquisition of the mutations after ART initiation. Twenty-one (47%) had an available pre-
ART plasma sample, which was used to genotype the virus prior to ART exposure. Five of 21 
patients harboured DRM but only one child was on an inactive treatment regimen at ART 
initiation. For another ten patients, we analysed stored samples from their mothers, who were 
still on a first-line ART. All were virologically suppressed, arguing against a vertical 
transmission of the respective drug resistant-viruses and suggesting that HIV-DRM emerged 
only after treatment initiation. Of the remaining 13 children, only CD4+ T cell count and 
percentage data was available for assessing treatment efficacy. No pre-ART sample of these 
children had been stored, and their mothers either had been switched to second-line ART or 
were dead. Eight out of these 13 patients demonstrated stable or increasing CD4+ T cell 
counts and percentages after treatment initiation, suggesting initial drug activity, thereby 
further decreasing the likelihood of vertical transmission of a resistant virus. The remaining 
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five children experienced no elevation of CD4+ T cell counts or percentages or even showed 
declining values, which suggest either poor adherence to ART or transmission of a resistant 
virus from their mothers. Taken together, these data suggest that at least 86.4% of participants 
(38/44, 95% CI 76.2 - 96.5) acquired treatment-specific DRM after initiation of ART.  
  
Risk factors for the acquisition of HIV-DRM 
Table 2 summarizes the predictors of acquired DRM. NNRTI-based compared to PI-based 
current regimens (OR=10.73 [95% CI 1.75 – 65.70], p= 0.01) and female sex (OR=3.99 [95% 
CI 1.40 – 11.41], p=0.01) increased the odds of HIV-DRM. Additionally, poor adherence 
showed a trend towards increased odds in acquiring HIV-DRM (OR=3.72 [95% CI 0.90 – 
15.34], p=0.069). Older age (OR=0.81 per each additional year [95% CI 0.68 – 0.95], 
p=0.009) and higher CD4 percentages (OR=0.18 per additional 10% [95% CI 0.09 – 0.40], 
p<0.001) showed a protective effect.  
 
Sensitivity and specificity of WHO immunological criteria to detect treatment failure 
The current WHO immunological criteria of treatment failure for children (CD4+ T cell count 
below 200 cells/µL or CD4+ T cell percentage below 10% for children under five years of age 
and CD4+ T cell count below 100 cells/µL for children aged 5 to 15 years) correctly classified 
2/54 (3.7%) children with VF. The sensitivity of the immunological criteria after including 
adolescents (CD4+ T cell count dropping to the pre-ART level or below) to detect VF rose to 
14%. As only one patient would have been mistakenly classified with VF, the specificity of 
these WHO criteria reached 99.3%.  
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Discussion 
To our knowledge, this is one of the first studies to comprehensively assess VF and the 
acquisition of HIV-DRM among a large paediatric population in SSA. Key findings are a high 
rate of both VF and acquired HIV-DRM after a median of over 4 years on ART and an 
increased risk of both VF and HIV-DRM among participants receiving NNRTI, those with 
younger age at ART initiation and female patients.  
The VF rate of 25.4% exceeded by far the 9.1% failure rate observed for the adult population 
in the same cohort [25], emphasizing the great challenge to successfully suppress HIV in 
paediatric patients. However, the high VF rate found in our study is comparable to previous 
reports from similar East and West African settings [10,15,26-30]. Of note, it is significantly 
lower than the actual national Tanzanian average of 38.8% elaborated by the Tanzanian CDC 
[31], which could be partially attributed to the specialised counsellors and clinicians in our 
paediatric unit. 
The prevalence of HIV-DRM of 90.4% in children and adolescents with VF in our cohort is 
comparable with similar settings [10,29-30] and the adult population in our clinic [32]. The 
multi-class resistances, present in almost 80% of all failing patients dramatically limits future 
treatment options and represents an important public health concern. The presence of the 
K65R mutation in three patients is also concerning, as this triggers resistance to TDF and 
abacavir (but not zidovudine) again limiting future treatment options. The observed 
prevalence of TDF-resistances in our setting was, however, much lower than in a recently 
published multicentre cohort study of patients failing to first-line ART [33]. Interestingly, the 
three patients with the multi-class resistance triggering K65R mutation had not been exposed 
to TDF. As already highlighted in other studies, stavudine (compared to zidovudine) may also 
select this multi-class resistance mutation [34]. Although stavudine is currently hardly used, 
this should be taken into account in patients previously treated with this drug. The absence of 
major PI mutations is reassuring. As PIs have a short half-life and a higher barrier to 
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resistance, it has been suggested that they are less likely to allow the emergence of drug 
resistance mutations in early VF [35-37]. Of note, patients on PI-based second-line treatment 
also received additional counselling. Overall, these results indicate that PI-based second-line 
regimens potently suppress HIV in children and adolescents. However, new drug classes such 
as integrase inhibitors and new paediatric drug combinations are strongly needed in this 
setting to be able to treat individuals with multi-class resistant virus. Even children with active 
second-line regimen will eventually depend on new drug classes as they rely on ART for 
decades, with growing risk to fail on the second-line. Although recycled NRTIs show residual 
activity in adult populations [38-39], these results cannot be extrapolated to paediatric 
populations.  
In 86.4% of the patients with HIV-DRM, the resistant viral variants likely emerged after ART 
initiation. However, as imperfect adherence of the mother during pregnancy would lead to the 
possible archiving of drug resistant proviruses, it cannot be excluded that in these cases viral 
minorities carrying resistance-associated mutations were also transmitted to the offspring. 
Such virus would then only emerge once drug pressure with the respective drug was applied. 
As stated above, although this possibility cannot completely be ruled out, our analysis renders 
this explanation unlikely for most of the observed resistance cases: no recorded failure of the 
mother, initial period of treatment success in the child, and paediatric regimen different from 
the mother‟s therapy. 
Poor adherence predicted VF and showed a trend to predicting the acquisition of HIV-DRM. 
Adherence is dependent on drug, social, health system and health workers‟ factors [6,40]. The 
development of new child-friendly drug formulations is needed. In addition, a functioning 
procurement and distribution system is crucial and tools to facilitate the prescription of 
paediatric drugs need to be widely disseminated and routinely used. In our cohort, the number 
of treatment switches significantly increased the odds for poor adherence (by 58%) and for 
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being under-dosed for each additional change of treatment (by 50%) (Table S1). It is essential 
to minimise treatment switches in this context to improve adherence. 
Younger age at ART start, NNRTI-based regimens and female sex were identified as risk 
factors for VF and the acquisition of HIV-DRM. Sub-therapeutic drug levels in younger 
children due to difficulties to administer the drugs, faster metabolism, differences in 
pharmacokinetics and dose-prescribing errors could explain this finding [7,9,27,41]. 
Additional sub-group analysis revealed that 35.2% (19/54) of the study participants with VF 
were prescribed a drug dose below the recommended for the patient‟s body weight at least 
once since ART was initiated, as previously highlighted by a study among this same 
paediatric population [42]. Of note, after a dedicated paediatric unit had been established in 
our clinic, such dosing errors were eliminated [42]. Children and adolescents on NNRTI-
based regimens had much higher odds to experience VF and to acquire DRM than participants 
on PI-based regimens, again suggesting the good performance of PI regimens in suppressing 
HIV and preventing DRM. As mentioned above, the additional counselling in patients on PI-
based second-line treatment might have slightly biased this finding. Girls were more 
vulnerable to VF and the development of HIV-DRM for reasons that could not be explained 
in the framework of this study, but indeed sex inequalities were also found in other recent 
studies from East Africa [43]. 
 The WHO criteria for immunological failure showed an alarmingly low sensitivity of 5% in 
children and 14% in adolescents. For most of the study participants with VF, the CD4+ T cell 
counts stayed above 20% and 500 cells/µL after initial immune cell recovery, values 
considerably higher than the WHO recommended criteria for immunological failure [24]. A 
similar study from Rwanda revealed that even a threshold of <350 CD4+ T cells/µL to detect 
treatment failure had a very low sensitivity ranging from 19% to 32% [15]. The late detection 
of patients with treatment failure leads to the accumulation of drug resistances and 
dramatically limits treatment options [10,44]. The implementation and up-scaling of VL 
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monitoring is essential to maintain treatment options and optimize health outcomes in 
resource-limited setting with restricted treatment possibilities [6,10,29].  
A limitation of this study was the definition of VF as a single VL ≥1000 copies/mL, which 
has a lower sensitivity than the official WHO definition for VF. It is possible that children 
with lower VL also carry DRM, though. Furthermore, the use of population sequencing for 
genotyping might have led to an underestimation of drug resistance mutations also in pre-
ART samples. Our assessment for acquisition of DRM compared to transmitted DRM may 
have allowed some transmitted DRM to remain unnoticed by sequencing pre-ART samples. 
In addition, a suppressed VL of the mother on first-line treatment does not ultimately exclude 
transmission of DRM. 
 
In conclusion, our study found high rates of VF and emerging HIV-DRM in this paediatric 
population on long-term ART in rural Tanzania. Both VF and the emergence of HIV-DRM 
were associated with NNRTI use, younger age at ART initiation, poor adherence, and female 
sex. Moreover, our results reinforce the current knowledge about the low sensibility of the 
WHO criteria for immunological treatment failure in children and adolescents. These findings 
provide relevant information for clinicians and health policy makers and raise concerns about 
the effectiveness of current paediatric ART programmes in SSA, calling for a critical review 
of current guidelines. In particular, awareness needs to be raised in order to advocate for the 
strengthening of adherence strategies tailored to this vulnerable population, the development 
and widespread availability of new paediatric ART formulations, and the universal roll-out of 
routine VL monitoring for the millions of children and adolescents living with HIV in SSA.  
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241 children and adolescents ≥12 
months on ART 
213 children and 
adolescents eligible and 
analysed during study 
Virologic success  
(VL < 1000 copies/mL): 
159 (74.6%) 
Virologic failure 
(VL ≥ 1000 copies/mL): 
54 (25.4%) 
HIV drug resistance 
mutations: 
47/52 (90.4%) 
Unsuccsessful viral 
genotyping 
n=2 
 28 participants excluded: 
  -13: without any sample 
  -12: sample stored before 12 months on ART 
    -2: samples not available 
    -1: missclassified as a child  
Figure 1. Profile of the paediatric study cohort at the Chronic Disease Clinic Ifakara in Ifakara, Morogoro, Tanzania, with 
virologic outcomes and the presence of drug resistance mutations. 
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A. Participants without virologic failure 
 
 
n= 
 
108    84    94     83    78      68     60     48      56     59      61     54     45     94  
 
 
Figure 2. CD4
+
 T cell percentage recovery 
among the 213 children analysed within 
this study.  
The horizontal line within each box 
represents the median CD4
+
 cell 
percentage, the top and bottom of the box 
mark the 75
th
 and the 25
th
 percentiles, 
respectively. The upper and lower bound 
of the whiskers represent the largest and 
lowest values within the 75
th
 percentile + 
1.5x IQR and the 25
th
 percentile – 1.5x IQR, 
respectively. Data points beyond these 
intervals are shown as filled circles and 
represent outliers. A.) All participants with 
virologic success are represented in the 
plot, showing a stable CD4
+
 percentage 
recovery after ART initiation. B.) 
Participants with virologic failure are 
illustrated within this plot, showing an 
initial CD4
+
 percentage recovery, which is 
less stable than the one from patients 
without VF, though.  The time on ART 
always includes the interval from the 
previous month up to the one indicated 
below the axis (e.g. 6= >0 & ≤6). 
 B. Participants with virologic failure 
 
 
 
n= 
 
32     29      33     26     25     33     22     21     26     15     16      10     14     30 
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Table 1. Characteristics of children and adolescents enrolled in the Kilombero and Ulanga Antiretroviral Cohort that had 
been on antiretroviral treatment for at least 12 months. 
Characteristics n* 
 
Overall cohort 
(N=213) 
Virologic success 
(n=159) 
Virologic failure 
(n=54) 
Female (%) 
 
213 92 (43.2) 65 (40.9) 27 (50) 
Age, years (IQR) 
 
213 11.0 (7.5-14.4) 11.2 (7.6-13.8) 10.3 (7.2-15.2) 
Age at ART initiation, years (IQR) 206 6.4 (3.1-9.5) 6.3 (3.9-9.3) 7.2 (2.5-9.7) 
Time on ART, years (IQR) 209 4.45 (2.4-6.0) 4.5 (2.4-6.1) 4.1 (2.5-5.6) 
Any prior ART exposure (%) 193 24 (12.4) 19 (13.1) 5 (10.4) 
Current CD4 count in cells/µL, median 
(IQR) 
176 636 (440-901) 680 (477-911) 485 (364-881) 
CD4 count in cells/µL at pre-ART, median 
(IQR) 
139 295 (123-561) 292 (134-523) 318 (78-643) 
Current CD4 percent, median (IQR) 171 29 (23-34.1) 30.2 (24.8-35.9) 24.4 (15-29) 
CD4 percent at pre-ART, median (IQR) 137 12.2 (6.3-19.3) 13 (7-18.6) 9.8 (2.7-21.5) 
Current WHO clinical stage 3-4 (%) 209 141 (67.5) 104 (67.1) 37 (68.5) 
WHO clinical stage 3-4 at pre-ART (%) 186 102 (54.8) 79 (57.3) 23 (57.9) 
Distance to CTC (km) 183 1 (1-25) 1 (1-25) 1 (1-33) 
Good adherence
1
 (%) 213 184 (86.4) 142 (89.3) 42 (77.8) 
Lost to follow-up since last visit
2
 (%) 213 10 (4.7) 7 (4.4) 3 (5.6) 
Initial ART regimen (%) 
d4T+3TC+NVP 
AZT+3TC+NVP 
AZT+3TC+EFV 
Others 
195  
76 (39) 
37 (19) 
70 (36) 
12 (6) 
 
58 (39.5) 
24 (16.3) 
56 (38.1) 
9 (6.1) 
 
18 (37.5) 
13 (27.1) 
14 (29.2) 
3 (6.2) 
Current ART regimen (%) 
PI-based regimen  
NNRTI-based regimen 
Others 
213  
32 (15.0) 
179 (84.0) 
2 (1.0) 
 
24 (15.1) 
135 (84.9) 
0 (0) 
 
8 (14.8) 
44 (81.5) 
2 (3.7) 
Number of regimen switches (IQR) 213 3 (2-5) 3 (2-5) 4 (2-5) 
ART change due to stock-out (%) 213 50 (23.5) 36 (22.6) 14 (25.9) 
BMI for age z-score (IQR) 209 -0,74 (-1,42 to -0,03) -0,82 (-1,5 to -0,12) -0,57 (-1,39 to 0,16) 
Weight for height z-score
3
 (IQR) 14 0,21 (0,01 to 1,08) 0,14 (0,1 to 0,76) 
(n=9) 
0,71 (0,08 to 1,1) 
(n=5) 
1
Defined as any missed dose during the last four weeks, reported by the patient or their caregiver 
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2
Last visit more than 6 months + 60 days 
3
Includes only children < 5 years (n=14) 
*Number of patients with non-missing values 
IQR: interquartile range; ART: antiretroviral treatment; CTC: care and treatment centre; d4T: stavudine; 3TC: lamivudine; NVP: 
nevirapine; AZT: zidovudine; EFV: efavirenz, PI: protease inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; BMI: body 
mass index. 
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Table 2. Predictors of virologic failure and acquired HIV drug resistance mutations among children and adolescents attending the Chronic Disease Clinic in Ifakara using logistic regression analysis. 
 Virologic Failure Acquisition of HIV-DRM 
 Univariate Multivariate Univariate Multivariate 
 OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p 
Female 1.45 0.78 – 2.69 0.244 2.57 1.03–6.45 0.044 1.82 0.89 – 3.70 0.101 3.99 1.40 – 11.41 0.010 
Current CD4
+
 percentage per 
additional 10 percent 
0.40 0.26 – 0.62 <0.001 0.20 0.10 - 0.40 <0.001 0.48 0.31 – 0.75 0.001 0.18 0.09 – 0.40 <0.001 
CD4
+
 cell percentage at ART 
initiation per additional 10 
percent 
0.97 0.71 – 1.33 0.870 - - - 1.15 0.83 – 1.58 0.404 - - - 
WHO clinical stage 3-4 at ART 
initiation 
0.69 0.36 – 1.33 0.264 0.73 0.29 - 1.86 0.513 0.75 0.36 – 1.55 0.430 0.78 0.27 – 2.21 0.640 
Age at ART initiation per each 
additional year 
1.02 0.94 – 1.10 0.671 0.84 0.73–0.97 0.017 0.96 0.87 – 1.05 0.354 0.81 0.68 – 0.95 0.009 
Poor adherence
1
 2.39 1.06 – 5.39 0.037 3.90 1.11 - 13.68 0.034 2.15 0.85 – 5.40 0.104 3.72 0.90 – 15.34 0.069 
BMI-for-age Z score
2
 1.11 0.86 – 1.42 0.433 0.97 0.70 - 1.35 0.875 1.11 0.84 – 1.47 0.465 0.99 0.69 – 1.41 0.954 
Initial ART regimen compared 
to d4T+3TC+NVP 
AZT+3TC+NVP 
AZT+3TC+EFV 
Others 
 
 
1.75 
0.81 
1.07 
 
 
0.74 – 4.11 
0.37 – 1.77 
0.26 – 4.40 
 
 
0.203 
0.591 
0.921 
 
 
2.13 
1.09 
1.72 
 
 
0.56 – 8.10 
0.36 – 3.30 
0.23 – 12.58 
 
 
0.269 
0.884 
0.596 
 
 
1.82 
1.24 
1.82 
 
 
0.65 – 5.08 
0.52 – 3.00 
0.42 – 7.80 
 
 
0.254 
0.627 
0.421 
 
 
2.96 
1.79 
3.76 
 
 
0.69 – 12.79 
0.50 – 6.41 
0.45 – 31.30 
 
 
0.145 
0.371 
0.220 
NNRTI-based ART regimen 
compared to PI-based  
0.78 0.35 – 1.76 0.553 7.32 1.51 – 35.46 0.013 1.54 0.50 – 4.72 0.450 10.73 1.75 – 65.70 0.010 
Orphan (single or double) 0.67 0.32 – 1.41 0.287 0.63 0.21 – 1.86 0.398 0.65 0.29 – 1.49 0.310 0.89 0.26 – 3.04 0.846 
ART switch by stock-out 1.20 0.59 – 2.44 0.623 1.39 0.45 – 4.33 0.571 0.99 0.43 – 2.26 0.975 1.38 0.38 – 4.98 0.624 
Number of ART switches
3
 1.04 0.94 – 1.16 0.400 0.99 0.82 – 1.20 0.944 1.01 0.90 – 1.14 0.867 0.93 0.75 – 1.16 0.535 
Distance to clinic
4
 1.01 0.91 – 1.12 0.854 - - - 1.00 0.99 – 1.01 0.825 - - - 
Transferred to CDCI after 
treatment initiation 
0.77 0.27 – 2.19 0.626 - - - 0.83 0.26 – 2.59 0.743 -   - - 
1
defined as any missed dose during the last four weeks, reported by the patient or their caregiver 
2
 per each additional unit increase of the z-score 
3
per each additional number of regimen switch 
4
per each additional kilometre distance to the hospital 
ART: antiretroviral treatment; CTC: care and treatment centre; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; AZT: zidovudine; EFV: efavirenz, PI: protease inhibitor; NNRTI: non-nucleoside 
reverse transcriptase inhibitor; BMI: body mass index; CDCI: Chronic Disease Clinic Ifakara. 
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Table 3. Detected drug resistance mutations and respective number of children and adolescents after experienced virologic 
failure, by drug class.  
From the 54 patients with VF, 52 were successfully genotyped. Mutations occurring also as mixtures with the wild type 
sequence are indicated by an asterisk. 
 
NRTI-associated DRM 
HIV drug resistance mutations Number of patients with mutations 
M184V* 
T215F/Y 
K219Q/E 
K70R 
D67N 
M41L 
T69N/D/G 
K65R, L210W 
A62V 
V75M 
40 (77%) 
13 (25%) 
11 (21%) 
10 (19%) 
9 (17%) 
5 (10%) 
4 (8%) 
3 (6%) 
2 (4%) 
1 (2%) 
 
NNRTI-associated DRM 
HIV drug resistance mutations Number of patients with mutations 
K103N* 
Y181C*/V 
G190A* 
E138A/G/Q 
K101E/P 
V108I 
A98G 
V90I*, L100I/V, Y188L, P225H* 
K238T 
V106M, V179D, H221Y, M230L 
F227L 
25 (49%) 
16 (31%) 
12 (24%) 
10 (20%) 
9 (18%) 
7 (14%) 
5 (10%) 
4 (8%) 
3 (6%) 
2 (4%) 
1 (2%) 
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